No overdiagnosis in the Norwegian Breast Cancer Screening Program estimated by combining record linkage and questionnaire information in the Norwegian Women and Cancer study.

[1]  I. Vejborg,et al.  Overdiagnosis in breast cancer screening: The impact of study design and calculations. , 2017, European Journal of Cancer.

[2]  H. D. de Koning,et al.  Breast cancer incidence trends in Norway and estimates of overdiagnosis , 2017, Journal of medical screening.

[3]  Amy Cantor,et al.  Harms of Breast Cancer Screening: Systematic Review to Update the 2009 U.S. Preventive Services Task Force Recommendation , 2016, Annals of Internal Medicine.

[4]  Stephen W Duffy,et al.  Screen detection of ductal carcinoma in situ and subsequent incidence of invasive interval breast cancers: a retrospective population-based study , 2016, The Lancet. Oncology.

[5]  Gillian D Sanders,et al.  Benefits and Harms of Breast Cancer Screening: A Systematic Review. , 2015, JAMA.

[6]  Rediet Abebe,et al.  Breast Cancer Screening, Incidence, and Mortality Across US Counties. , 2015, JAMA internal medicine.

[7]  S. Duffy,et al.  Effect of mammographic screening from age 40 years on breast cancer mortality in the UK Age trial at 17 years' follow-up: a randomised controlled trial. , 2015, The Lancet. Oncology.

[8]  K. Straif,et al.  Breast-cancer screening--viewpoint of the IARC Working Group. , 2015, The New England journal of medicine.

[9]  Eugenio Paci,et al.  European Breast Cancer Service Screening Outcomes: A First Balance Sheet of the Benefits and Harms , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[10]  J. Ursini-Siegel,et al.  Peripheral blood cells inform on the presence of breast cancer: A population-based case–control study , 2014, International journal of cancer.

[11]  Peter Jüni,et al.  Abolishing mammography screening programs? A view from the Swiss Medical Board. , 2014, The New England journal of medicine.

[12]  Joann G Elmore,et al.  Mammographic performance in a population-based screening program: before, during, and after the transition from screen-film to full-field digital mammography. , 2014, Radiology.

[13]  L. Esserman,et al.  Mammographic screening detects low-risk tumor biology breast cancers , 2014, Breast Cancer Research and Treatment.

[14]  J. Thalabard,et al.  Overdiagnosis of breast cancer in the Norwegian Breast Cancer Screening Program estimated by the Norwegian Women and Cancer cohort study , 2013, BMC Cancer.

[15]  J. Reis-Filho,et al.  Progression from ductal carcinoma in situ to invasive breast cancer: Revisited , 2013, Molecular oncology.

[16]  P. Gøtzsche,et al.  Screening for breast cancer with mammography. , 2013, The Cochrane database of systematic reviews.

[17]  P. Møller,et al.  Survival of patients with BRCA1-associated breast cancer diagnosed in an MRI-based surveillance program , 2013, Breast Cancer Research and Treatment.

[18]  P. Skaane,et al.  Overdiagnosis among women attending a population-based mammography screening program , 2013, International journal of cancer.

[19]  D. Altman,et al.  The benefits and harms of breast cancer screening: an independent review , 2012, British Journal of Cancer.

[20]  Eugenio Paci,et al.  Overdiagnosis in Mammographic Screening for Breast Cancer in Europe: A Literature Review , 2012, Journal of medical screening.

[21]  H. Adami,et al.  Overdiagnosis of Invasive Breast Cancer Due to Mammography Screening: Results From the Norwegian Screening Program , 2012, Annals of Internal Medicine.

[22]  M. Kumle,et al.  Mammography activity in Norway 1983 to 2008 , 2011, Acta oncologica.

[23]  H. D. de Koning,et al.  Interpreting Overdiagnosis Estimates in Population-based Mammography Screening , 2011, Epidemiologic reviews.

[24]  J. Hallas,et al.  Type of hormone therapy and risk of misclassification at mammography screening , 2010, Menopause.

[25]  H. Welch,et al.  Overdiagnosis in cancer. , 2010, Journal of the National Cancer Institute.

[26]  Peter C Gøtzsche,et al.  Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends , 2009, BMJ : British Medical Journal.

[27]  Odd O Aalen,et al.  Estimating mean sojourn time and screening sensitivity using questionnaire data on time since previous screening , 2008, Journal of medical screening.

[28]  M. Kumle,et al.  Cohort profile: The Norwegian Women and Cancer Study--NOWAC--Kvinner og kreft. , 2008, International journal of epidemiology.

[29]  A. Eggen,et al.  Hormone replacement therapy and incidence of hormone‐dependent cancers in the Norwegian Women and Cancer study , 2004, International journal of cancer.

[30]  Jan Mæhlen,et al.  Incidence of breast cancer in Norway and Sweden during introduction of nationwide screening: prospective cohort study , 2004, BMJ : British Medical Journal.

[31]  Lund Eiliv,et al.  External validity in a population-based national prospective study – the Norwegian Women and Cancer Study (NOWAC) , 2003, Cancer Causes & Control.

[32]  O. M. Jensen,et al.  Cancer Registration: Principles and Methods , 1991 .